KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Short term Debt: 2017-2019

Historic Short term Debt for Xenon Pharmaceuticals (XENE) over the last 2 years, with Dec 2019 value amounting to $4.7 million.

  • Xenon Pharmaceuticals' Short term Debt was N/A to $15.7 million in Q1 2020 from the same period last year, while for Mar 2020 it was $15.7 million, marking a year-over-year change of. This contributed to the annual value of $4.7 million for FY2019, which is N/A change from last year.
  • According to the latest figures from FY2019, Xenon Pharmaceuticals' Short term Debt is $4.7 million, which was up 564.29% from $700,000 recorded in FY2017.
  • Over the past 5 years, Xenon Pharmaceuticals' Short term Debt peaked at $4.7 million during FY2019, and registered a low of $700,000 during FY2017.
  • Over the past 2 years, Xenon Pharmaceuticals' median Short term Debt value was $2.7 million (recorded in 2017), while the average stood at $2.7 million.